Stock Screener App

Gratuito -

Installare

Drug Manufacturers - Specialty & Generic

145.26

1.14% -1.67

after-market

Dopo l'orario di chiusura: 145.26

Neurocrine Biosciences Inc (NBIX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Storia dei dividendi

Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie

Neurocrine Biosciences, Inc. $NBIX Shares Sold by Rice Hall James & Associates LLC - MarketBeat

Neurocrine Biosciences director sells shares worth $269,167 - MSN

Swedbank AB Has $76.83 Million Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Neurocrine Biosciences (NBIX) Stock News: Brighton Jones Raises Stake to $1.43M - Eudaimonia and Co

Brighton Jones LLC Has $1.43 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Neurocrine Biosciences Earnings Notes - Trefis

AbbVie, Neurocrine End One Orilissa Patent Case Against Hetero - Bloomberg Law News

Voya Investment Management LLC Cuts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

What's Going On With Neurocrine Biosciences Stock Tuesday?Neurocrine Biosciences (NASDAQ:NBIX) - Benzinga

Neurocrine’s valbenazine misses Phase III goals in DCP - The Pharma Letter

Neurocrine Biosciences (NBIX): Assessing Valuation After New Phase 2 Bipolar I Mania Trial Launch - Sahm

Neurocrine : Phase 3 Study Of Valbenazine In Dyskinetic Cerebral Palsy Fails To Meet Main Goal - Nasdaq

Neurocrine's Ingrezza fails in phase 3 trial for dyskinetic cerebral palsy (NBIX:NASDAQ) - Seeking Alpha

Neurocrine's movement disorder treatment fails late-stage trial - marketscreener.com

Neurocrine's Phase 3 Trial of Valbenazine in Dyskinetic Cerebral Palsy Fails to Meet Primary, Key Secondary Endpoints - marketscreener.com

Neurocrine’s phase 3 trial for cerebral palsy drug fails to meet endpoints - Investing.com

Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy - PR Newswire

Assenagon Asset Management S.A. Sells 13,280 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Neurocrine’s Growth Story Runs Through INGREZZA And The Pipeline - Finimize

HC Wainwright & Co. maintains Neurocrine Biosciences (NBIX) buy recommendation - MSN

What hedge fund activity signals for Neurocrine Biosciences Inc. stock2025 Valuation Update & Weekly Sector Rotation Insights - Bölüm Sonu Canavarı

How Neurocrine Biosciences Inc. stock valuations compare to rivals2025 Volatility Report & Fast Gaining Stock Reports - Улправда

Merger Talk: Can Neurocrine Biosciences Inc. stock beat analyst upgrades2025 EndofYear Setup & Risk Managed Investment Entry Signals - moha.gov.vn

Is Neurocrine Biosciences (NBIX) Quietly Recasting Its Long-Term Story Around Metabolic Disease Innovation? - simplywall.st

How Neurocrine Biosciences Inc. (NB3) stock reacts to monetary easing2025 Earnings Surprises & Low Risk Entry Point Tips - ulpravda.ru

How Neurocrine Biosciences Inc. stock performs in weak economyQuarterly Earnings Summary & Weekly Hot Stock Watchlists - Улправда

Nxera Knocked Back As Boehringer Bows Out Of Schizophrenia Pact - Citeline News & Insights

Is Neurocrine Biosciences Inc. (NB3) stock a momentum leaderPortfolio Gains Summary & Technical Pattern Recognition Alerts - DonanımHaber

Why Neurocrine Biosciences Inc. stock is favored by pension fundsQuarterly Market Summary & Growth Focused Entry Point Reports - DonanımHaber

Neurocrine Bio. stock price target raised to $198 by H.C. Wainwright - Investing.com Canada

Published on: 2025-12-18 16:31:37 - Улправда

RBC Capital Keeps Their Buy Rating on Neurocrine (NBIX) - The Globe and Mail

HC Wainwright & Co. Maintains Neurocrine Biosciences (NBIX) Buy Recommendation - Nasdaq

Neurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk Sells 1,190 Shares - MarketBeat

Neurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk Sells 5,000 Shares - MarketBeat

Neurocrine Biosciences Director Sells Shares - TradingView — Track All Markets

Neurocrine Bio. stock price target reiterated at $200 by TD Cowen - Investing.com Canada

Key facts: HC Wainwright maintains 'Buy' on Neurocrine; price target rises - TradingView — Track All Markets

Neurocrine Bio. stock holds Buy rating at Jefferies after R&D Day - Investing.com Canada

Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat

Neurocrine Bio. stock rating reiterated at Outperform by RBC Capital - Investing.com Canada

Texas Permanent School Fund Corp Sells 11,976 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Neurocrine showcases R&D across neuroscience and endocrinology - The Pharma Letter

Neurocrine Bio. stock holds steady as BMO reiterates $147 price target - Investing.com UK

Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology - PR Newswire

What analysts say about Neurocrine Biosciences Inc stockMomentum Trading Signals & Free Daily Top Stock Picks for All Investors - earlytimes.in

Dir Norwalk Files To Sell 11,250 Of Neurocrine Biosciences Inc [NBIX] - TradingView — Track All Markets

Hudson Bay Capital Management LP Has $9.75 Million Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Neurocrine Biosciences (NBIX): Revisiting Valuation After a Year of Double-Digit Shareholder Returns - simplywall.st

Thrivent Financial for Lutherans Cuts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat

Boone Capital Management LLC Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Neurocrine Biosciences, Inc. $NBIX is Braidwell LP's 3rd Largest Position - MarketBeat

Ieq Capital LLC Buys 35,956 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Mizuho raises Neurocrine Bio. stock price target to $175 on Crenessity outlook - Investing.com India

Neurocrine Biosciences, Inc. $NBIX Shares Purchased by California Public Employees Retirement System - MarketBeat

Neurocrine Biosciences, Inc. $NBIX Shares Sold by Armistice Capital LLC - MarketBeat

Stifel Maintains Neurocrine Biosciences (NBIX) Buy Recommendation - Nasdaq

VTRS

$12.32

0.65%

RDY

$14.16

0.50%

ELAN

$22.60

0.98%

RGC

$21.16

13.98%

UTHR

$507.16

1.45%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters